Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth year-to-date. Pfizer’s stock price closed at $43.51 on November 16, which represents ~31% growth from its 52-week low of $33.20 on February 9.
On October 9, Pfizer hit its 52-week high of $45.81.
Financials in a nutshell
Pfizer’s net revenues during the first nine months of 2018 were $39.7 billion—compared to $38.8 billion during the same period in 2017, which reflects an increase of ~2% YoY (year-over-year). Pfizer’s Innovative Health segment and Essential Health segment generated revenues of $24.6 billion and $15.1 billion, respectively, during the first nine months of 2018, which reflects ~4% YoY growth and a ~6% YoY decline.
Pfizer expects its net revenues in 2018 to be $53.0 billion–$53.7 billion. Pfizer’s oncology, vaccines, and biosimilars pushed the revenue growth during the first nine months of 2018. Pfizer’s peers in the biopharmaceutical market, Amgen (AMGN) and Bristol-Myers Squibb (BMY) generated revenues of $5.9 billion and $45.7 billion, respectively, in the third quarter, which reflects ~2.27% and ~8.32% YoY growth.
Pfizer’s net income and diluted EPS during the first nine months of 2018 were $11.5 billion and $1.92, respectively—compared to its net income and diluted EPS of $9.0 billion and $1.49 during the same period in 2017, which reflects ~28% and ~29% YoY growth.
Pfizer’s revenue growth could boost the Health Care Select Sector SPDR Fund’s (XLV) share prices. Pfizer accounts for ~7.26% of XLV’s total portfolio holdings.
Among the 18 analysts tracking Pfizer in November, one recommended a “strong buy,” seven recommended a “buy,” eight recommended a “hold,” and two recommended a “strong sell.”
On November 19, Pfizer had a consensus 12-month target price of $43.79, which represents ~0.64% growth over the next 12 months.